Lyophilized powderTirzepatide
Tirzepatide (dual GIP/GLP-1 receptor agonist)
Tirzepatide is a synthetic 39-amino-acid peptide engineered from the native GIP sequence with structural modifications conferring agonism at both the GIP and GLP-1 receptors. A C20 fatty diacid moiety supports albumin binding and extended half-life. Its research interest lies substantially in the question of whether dual incretin agonism produces effects distinguishable from GLP-1 monoagonism.
Research applications
- Dual incretin receptor signaling and biased agonism studies
- Comparative studies against selective GLP-1 agonists
- cAMP accumulation and β-arrestin recruitment assays
- Adipose and hepatic metabolic pathway research
Storage
Store lyophilized powder at -20°C protected from light. Reconstituted solution stable at 2-8°C for up to 30 days.
Reconstitution
Reconstitute with bacteriostatic water directed down the vial wall. Swirl gently — do not shake or vortex.
Published literature
2,273 papers indexed on PubMed for Tirzepatide. Showing 6, reviews first.
- 01Tirzepatide for overweight and obesity management
Hamza M et al. · Expert Opin Pharmacother · 2025
- 02Tirzepatide: A Review in Type 2 Diabetes
France NL, Syed YY · Drugs · 2024
- 03Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)
Wilson L et al. · Diabetes Obes Metab · 2026
- 04Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne LJ et al. · N Engl J Med · 2025
- 05Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
Rodriguez PJ et al. · JAMA Intern Med · 2024
- 06Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
Zeng Q et al. · Front Endocrinol (Lausanne) · 2023
Indexed from PubMed, 2026-07-19. We link to sources rather than reproducing them.
Related compounds
Low stockSemaglutide
5–20mg · ≥99% pure
Long-acting GLP-1 receptor agonist studied extensively for incretin pathway signaling and glucose regulation in preclinical models.
- CAS
- 910463-68-2
- MW
- 4113.58
- Purity
- ≥99%
Low stockRetatrutide
10–30mg · ≥99% pure
Triple agonist at GIP, GLP-1, and glucagon receptors — among the most actively studied compounds in current metabolic research.
- CAS
- 2381089-83-2
- MW
- 4731.32
- Purity
- ≥99%
Cagrilintide
10mg · ≥99% pure
Long-acting amylin analog studied at calcitonin and amylin receptors — a satiety pathway mechanistically distinct from incretin agonism.
- CAS
- 1415456-99-3
- MW
- 4409
- Purity
- ≥99%
AOD-9604
5mg · ≥99% pure
C-terminal fragment of human growth hormone studied for lipolytic activity without the growth-promoting effects of the full hormone.
- CAS
- 221231-10-3
- MW
- 1815.08
- Purity
- ≥99%